• Artelo published a review in the British Journal of Clinical Pharmacology analyzing more than 50 studies of low-dose, non-prescription CBD products.
• The analysis found little to no evidence of biological effect or therapeutic value at ≤2.5 mg/kg or ≤175 mg/day, typical of retail dosing.
• Oral CBD exposures in the reviewed studies were 5-100 times below levels associated with regulator-approved epilepsy dosing.
• Drug-drug interaction signals were flagged with commonly used medicines, raising safety considerations despite generally good tolerability.
• The findings support development of higher-bioavailability CBD formulations such as the company’s ART12.11 cocrystal tablet candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220839PRIMZONEFULLFEED9766057) on July 22, 2026, and is solely responsible for the information contained therein.